JNJ

230.35

+2.69%↑

ABT

90.92

-1.2%↓

MDT

82.98

-0.12%↓

112.52

-7.07%↓

VEEV

152.76

-6.53%↓

JNJ

230.35

+2.69%↑

ABT

90.92

-1.2%↓

MDT

82.98

-0.12%↓

112.52

-7.07%↓

VEEV

152.76

-6.53%↓

JNJ

230.35

+2.69%↑

ABT

90.92

-1.2%↓

MDT

82.98

-0.12%↓

112.52

-7.07%↓

VEEV

152.76

-6.53%↓

JNJ

230.35

+2.69%↑

ABT

90.92

-1.2%↓

MDT

82.98

-0.12%↓

112.52

-7.07%↓

VEEV

152.76

-6.53%↓

JNJ

230.35

+2.69%↑

ABT

90.92

-1.2%↓

MDT

82.98

-0.12%↓

112.52

-7.07%↓

VEEV

152.76

-6.53%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Avatud

SektorTervishoid

32.21 1.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

31.29

Max

32.62

Põhinäitajad
By Trading Economics
Sissetulek	-28M 22M
Müük	4.3M 244M
P/E Sektori keskmine	10.897 60.328
Kasumimarginaal	9.224
Töötajad	293
EBITDA	-22M 52M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+34.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	161M 1.7B
Eelmine avamishind	30.5
Eelmine sulgemishind	32.21

Uudiste sentiment

By Acuity

34%

66%

132 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Australian Flash PMI Bounce in April Conceals Deeper Worries

22. apr 2026, 23:33 UTC

Tulu

SK Hynix Posts Record Quarterly Results Amid AI Boom

22. apr 2026, 22:40 UTC

Tulu

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:11 UTC

Tulu

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22. apr 2026, 21:01 UTC

Tulu

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22. apr 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22. apr 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22. apr 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22. apr 2026, 23:16 UTC

Tulu

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22. apr 2026, 23:15 UTC

Tulu

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22. apr 2026, 22:52 UTC

Tulu

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22. apr 2026, 22:51 UTC

Tulu

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22. apr 2026, 22:30 UTC

Tulu

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22. apr 2026, 22:30 UTC

Tulu

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22. apr 2026, 22:29 UTC

Tulu

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22. apr 2026, 22:27 UTC

Tulu

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22. apr 2026, 22:06 UTC

Market Talk

Tulu

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:47 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:37 UTC

Tulu

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22. apr 2026, 21:34 UTC

Tulu

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22. apr 2026, 21:29 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:20 UTC

Market Talk

Tulu

Tesla Expands Manufacturing to Chips -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

34.16% tõus

12 kuu keskmine prognoos

Keskmine 42.89 USD 34.16%

Kõrge 72 USD

Madal 25 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

132 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.